The flavin reductase MsuE is a novel nitroreductase that can efficiently activate two promising next-generation prodrugs for gene-directed enzyme prodrug therapy

Cancers

Volumn 5, Issue 3, 2013, Pages 985-997

  Green, Laura K ^a   Storey, Mathew A ^a   Williams, Elsie M ^a   Patterson, Adam V ^b,c   Smaill, Jeff B ^b,c   Copp, Janine N ^a,b   Ackerley, David F ^a,b  

^a VICTORIA UNIVERSITY OF WELLINGTON   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

CB1954; GDEPT; Gene therapy; Nitro CBI DEI; Nitroaromatic prodrug; Nitroreductase; PR 104A; SOS chromotest

Indexed keywords

2 (2 BROMOETHYL) 2 [[[(2 HYDROXYETHYL)AMINO]CARBONYL] 4,6 DINITROANILINO]ETHYL METHANESULFONATE; ANTINEOPLASTIC AGENT; NITRO CBI 5 [(DIMETHYLAMINO)ETHOXY]INDOLE; NITROREDUCTASE; OXIDOREDUCTASE; PR 104A; PRODRUG; PROTEIN MSUE; PROTEIN NFSA; PROTEIN NFSB; TRETAZICAR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIZATION; DRUG STRUCTURE; ESCHERICHIA COLI; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR PROBE; NUCLEOTIDE SEQUENCE; PSEUDOMONAS AERUGINOSA;

EID: 84881563479     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers5030985     Document Type: Article

References (34)

1. Dachs, G.U.; Hunt, M.A.; Syddall, S.; Singleton, D.C.; Patterson, A.V. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules 2009, 14, 4517-4545.
2. Portsmouth, D.; Hlavaty, J.; Renner, M. Suicide genes for cancer therapy. Mol. Aspects Med. 2007, 28, 4-41.
3. Rainov, N.G. A phase III clinical evaluation of HSV thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 2000, 11, 2389-2401.
4. Freytag, S.O.; Khil, M.; Stricker, H.; Peabody, J.; Menon, M.; DePeralta-Venturina, M.; Nafziger, D.; Pegg, J.; Paielli, D,Brown, S.; et al; Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002, 62, 4968-4976.
5. Tanaka, T.; Duflot-Dancer, A.; Tiraby, M.; Piccoli, C.; Tiraby, G.; Yamasaki, H.; Mesnil, M. Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: A partial contribution of gap junctions. Cancer Lett. 2009, 282, 43-47.
6. Chung-Faye, G.; Palmer, D.; Anderson, D.; Clark, J.; Downes, M.; Baddeley, J.; Hussain, S.; Murray, P.I.; Searle, P,Seymour, L.; et al; Virus-directed, enzyme prodrug therapy with nitroimidazole reductase: A phase I and pharmacokinetic study of its prodrug, CB1954. Clin. Cancer Res. 2001, 7, 2662-2668.
7. Patel, P.; Young, J.G.; Mautner, V.; Ashdown, D.; Bonney, S.; Pineda, R.G.; Collins, S.I.; Searle, P.F.; Hull, D,Peers, E.; et al; A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1954 [correction of CB1984]. Mol. Ther. 2009, 17, 1292-1299. Erratum in: Mol. Ther. 2009, 17, 1302.
8. Knox, R.J.; Friedlos, F.; Jarman, M.; Roberts, J.J. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 1988, 37, 4661-4669.
9. Anlezark, G.M.; Melton, R.G.; Sherwood, R.F.; Coles, B.; Friedlos, F.; Knox, R.J. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)-I. Purification and properties of a nitroreductase enzyme from Escherichia coli-A potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 1992, 44, 2289-2295.
10. Onion, D.; Patel, P.; Pineda, R.G.; James, N.; Mautner, V. Antivector and tumor immune responses following adenovirus-directed enzyme prodrug therapy for the treatment of prostate cancer. Hum. Gene Ther. 2009, 20, 1249-1258.
11. Prosser, G.A.; Copp, J.N.; Syddall, S.P.; Williams, E.M.; Smaill, J.B.; Wilson, W.R.; Patterson, A.V.; Ackerley, D.F. Discovery and evaluation of Escherichia coli nitroreductases that activate the anti-cancer prodrug CB1954. Biochem. Pharmacol. 2010, 79, 678-687.
12. Prosser, G.A.; Patterson, A.V.; Ackerley, D.F. uvrB gene deletion enhances SOS chromotest sensitivity for nitroreductases that preferentially generate the 4-hydroxylamine metabolite of the anti-cancer prodrug CB1954. J. Biotechnol. 2010, 150, 190-194.
13. Swe, P.M.; Copp, J.N.; Green, L.K.; Guise, C.P.; Mowday, A.M.; Smaill, J.B.; Patterson, A.V.; Ackerley, D.F. Targeted mutagenesis of the Vibrio fischeri flavin reductase FRase I to improve activation of the anticancer prodrug CB1954. Biochem. Pharmacol. 2012, 84, 775-783.
14. Prosser, G.A.; Copp, J.N.; Mowday, A.M.; Guise, C.P.; Syddall, S.P.; Williams, E.M.; Horvat, C.N.; Swe, P.M.; Ashoorzadeh, A,Denny, W.A.; et al; Creation and screening of a multi-family bacterial oxidoreductase library to discover novel nitroreductases that efficiently activate the bioreductive prodrugs CB1954 and PR-104A. Biochem. Pharmacol. 2013, 85, 1091-1103.
15. Wilson, W.R.; Pullen, S.M.; Hogg, A.; Helsby, N.A.; Hicks, K.O.; Denny, W.A. Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell cultures. Cancer Res. 2002, 62, 1425-1432.
16. Wilson, W.R.; Stribbling, S.M.; Pruijn, F.B.; Syddall, S.P.; Patterson, A.V.; Liyanage, H.D.S.; Smith, E.; Botting, K.J.; Tercel, M. Nitro-chloromethylbenzindolines: Hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators. Mol. Cancer Ther. 2009, 8, 2903-2913.
17. Green, L.K.; Syddall, S.P.; Carlin, K.M.; Bell, G.D.; Guise, C.P.; Mowday, A.M.; Hay, M.P.; Smaill, J.B.; Patterson, A.V.; Ackerley, D.F. Pseudomonas aeruginosa NfsB and nitro-CBI-DEI- A promising enzyme/prodrug combination for GDEPT. Mol. Cancer 2013, 12, 58.
18. Patterson, A.V.; Ferry, D.M.; Edmunds, S.J.; Gu, Y.; Singleton, R.S.; Patel, K.; Pullen, S.M.; Hicks, K.O.; Syddall, S.P,Atwell, G.J.; et al; Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin. Cancer Res. 2007, 13, 3922-3932.
19. Denny, W.A. Prospects for hypoxia-activated anticancer drugs. Curr. Med. Chem. Anticancer Agents 2004, 4, 395-399.
20. Barak, Y.; Thorne, S.H.; Ackerley, D.F.; Lynch, S.V.; Contag, C.H.; Matin, A. New enzyme for reductive cancer chemotherapy, YieF, and its improvement by directed evolution. Mol. Cancer Ther. 2006, 5, 97-103.
21. Theys, J.; Pennington, O.; Dubois, L.; Anlezark, G.; Vaughan, T.; Mengesha, A.; Landuyt, W.; Anné, J.; Burke, P.J,Dûrre, P.; et al; Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br. J. Cancer 2006, 95, 1212-1219.
22. Copp, J.N.; Williams, E.W.; Ackerley, D.F. Victoria University, Wellington, New Zealand. Unpublished work, 2013.
23. Roldán, M.D.; Pérez-Reinado, E.; Castillo, F.; Moreno-Vivián, C. Reduction of polynitroaromatic compounds: The bacterial nitroreductases. FEMS Microbiol. Rev. 2008, 32, 474-500.
24. Kertesz, M.A.; Schmidt-Larbig, K.; Wüest, T. A novel reduced flavin mononucleotide-dependent methanesulfonate sulfonatase encoded by the sulfur-regulated msu operon of Pseudomonas aeruginosa. J. Bacteriol. 1999, 181, 1464-1473.
25. Robinson, C.V.; Elkins, M.R.; Bialkowski, K.M.; Thornton, D.J.; Kertesz, M.A. Desulfurization of mucin by Pseudomonas aeruginosa: Influence of sulfate in the lungs of cystic fibrosis patients. J. Med. Microbiol. 2012, 61, 1644-1653.
26. Ernster, L.; Navazio, R. Soluble diaphorase in animal tissues. Acta Chem. Scand. 1958, 12, 595-602.
27. MrBayes. Available online: http://mrbayes.sourceforge.net/ (accessed on 23 July 2013).
28. Geneious, version 6.1; Biomatters: San Francisco, CA, USA, 2013.
29. NCBI. Available online: http://www.ncbi.nlm.nih.gov/pubmed/ (accessed on 23 July 2013).
30. Clustalw2. Available online: http://www.ebi.ac.uk/Tools/msa/clustalw2/ (accessed on 23 July 2013).
31. Bryant, D.W.; McCalla, D.R.; Leeksma, M.; Laneuville, P. Type I nitroreductases of Escherichia coli. Can. J. Microbiol. 1981, 27, 81-86.
32. Zenno, S.; Koike, H.; Kumar, A.N.; Jayaraman, R.; Tanokura, M.; Saigo, K. Biochemical characterization of NfsA, the Escherichia coli major nitroreductase exhibiting a high amino acid sequence homology to Frp, a Vibrio harveyi flavin oxidoreductase. J. Bacteriol. 1996, 178, 4508-4514.
33. Zenno, S.; Koike, H.; Tanokura, M.; Saigo, K,Gene cloning, purification, and characterization of NfsB, a minor oxygen-insensitive nitroreductase from Escherichia coli, similar in biochemical properties to FRase I, the major flavin reductase in Vibrio fischeri. J. Biochem. 1996, 120, 736-744.
34. Vass, S.O.; Jarrom, D.; Wilson, W.R.; Hyde, E.I.; Searle, P.F. E. coli NfsA: An alternative nitroreductase for prodrug activation gene therapy in combination with CB1954. Br. J. Cancer 2009, 100, 1903-1911.